Found: 104
Select item for more details and to access through your institution.
Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-31704-7
- By:
- Publication type:
- Article
Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data.
- Published in:
- Therapeutic Advances in Drug Safety, 2022, v. 13, p. 1, doi. 10.1177/20420986221146411
- By:
- Publication type:
- Article
Anticancer drug R&D landscape in China.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
High‐purity isolation platelets by gradient centrifugation plus filtration.
- Published in:
- International Journal of Laboratory Hematology, 2023, v. 45, n. 2, p. 187, doi. 10.1111/ijlh.13998
- By:
- Publication type:
- Article
Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 193, n. 1, p. 65, doi. 10.1007/s10549-022-06514-6
- By:
- Publication type:
- Article
Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 192, n. 1, p. 75, doi. 10.1007/s10549-021-06490-3
- By:
- Publication type:
- Article
Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 182, n. 3, p. 719, doi. 10.1007/s10549-020-05730-2
- By:
- Publication type:
- Article
Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy-a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines.
- Published in:
- Supportive Care in Cancer, 2015, v. 23, n. 1, p. 273, doi. 10.1007/s00520-014-2372-3
- By:
- Publication type:
- Article
Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1152681
- By:
- Publication type:
- Article
Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1056932
- By:
- Publication type:
- Article
KMT5A-methylated SNIP1 promotes triple-negative breast cancer metastasis by activating YAP signaling.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-29899-w
- By:
- Publication type:
- Article
Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
- Published in:
- Medical Science Monitor, 2020, v. 26, p. 1, doi. 10.12659/MSM.927187
- By:
- Publication type:
- Article
Sentinel node theory helps tracking of primary lesions of cancers of unknown primary.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 4, p. 462, doi. 10.1007/s10637-024-01442-2
- By:
- Publication type:
- Article
Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 2, p. 330, doi. 10.1007/s10637-021-01182-7
- By:
- Publication type:
- Article
Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1549, doi. 10.1007/s10637-021-01133-2
- By:
- Publication type:
- Article
Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 2, p. 507, doi. 10.1007/s10637-020-00903-8
- By:
- Publication type:
- Article
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
- Published in:
- Cancer Research & Treatment, 2020, v. 52, n. 4, p. 1059, doi. 10.4143/crt.2019.633
- By:
- Publication type:
- Article
Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211020528
- By:
- Publication type:
- Article
Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211022881
- By:
- Publication type:
- Article
Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211022881
- By:
- Publication type:
- Article
Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211020528
- By:
- Publication type:
- Article
Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.
- Published in:
- PLoS ONE, 2015, v. 10, n. 7, p. 1, doi. 10.1371/journal.pone.0133133
- By:
- Publication type:
- Article
Phase II Study of Pseudomonas aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2–Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane.
- Published in:
- PLoS ONE, 2015, v. 10, n. 3, p. 1, doi. 10.1371/journal.pone.0118607
- By:
- Publication type:
- Article
A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients.
- Published in:
- Molecular Cancer, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12943-022-01504-0
- By:
- Publication type:
- Article
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2729, doi. 10.1007/s00262-023-03434-2
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials.
- Published in:
- Cancers, 2023, v. 15, n. 10, p. 2858, doi. 10.3390/cancers15102858
- By:
- Publication type:
- Article
Chromatin Remodelling Molecule ARID1A Determines Metastatic Heterogeneity in Triple-Negative Breast Cancer by Competitively Binding to YAP.
- Published in:
- Cancers, 2023, v. 15, n. 9, p. 2447, doi. 10.3390/cancers15092447
- By:
- Publication type:
- Article
Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18 F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 16, p. 3973, doi. 10.3390/cancers14163973
- By:
- Publication type:
- Article
Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18 F-FES PET.
- Published in:
- Cancers, 2022, v. 14, n. 14, p. N.PAG, doi. 10.3390/cancers14143531
- By:
- Publication type:
- Article
Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer.
- Published in:
- International Journal of Nanomedicine, 2014, v. 9, p. 1443, doi. 10.2147/IJN.S58275
- By:
- Publication type:
- Article
Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial.
- Published in:
- BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02999-0
- By:
- Publication type:
- Article
Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11563-1
- By:
- Publication type:
- Article
Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 143, n. 1, p. 141, doi. 10.1007/s10549-013-2793-6
- By:
- Publication type:
- Article
Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 124, n. 3, p. 733, doi. 10.1007/s10549-010-1183-6
- By:
- Publication type:
- Article
BOLERO-5: a phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER + /HER2- advanced breast cancer.
- Published in:
- Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-01027-8
- By:
- Publication type:
- Article
First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00687-7
- By:
- Publication type:
- Article
Emerging roles of tripartite motif family proteins (TRIMs) in breast cancer.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 14, p. 1, doi. 10.1002/cam4.7472
- By:
- Publication type:
- Article
HS‐10352 in hormone receptor‐positive, HER2‐negative advanced breast cancer: A phase 1 dose‐escalation trial.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 24, p. 21849, doi. 10.1002/cam4.6755
- By:
- Publication type:
- Article
A study of clinical and molecular characteristics in bilateral primary breast cancer.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 15, p. 15881, doi. 10.1002/cam4.6226
- By:
- Publication type:
- Article
Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in China: An analysis of 1420 cases.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 2, p. 1177, doi. 10.1002/cam4.4973
- By:
- Publication type:
- Article
Heterogeneity derived from <sup>18</sup>F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 9, p. 1948, doi. 10.1002/cam4.4522
- By:
- Publication type:
- Article
Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation‐wide multicenter study.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 19, p. 6744, doi. 10.1002/cam4.4215
- By:
- Publication type:
- Article
Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 23, p. 8821, doi. 10.1002/cam4.3491
- By:
- Publication type:
- Article
A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple‐negative breast cancer.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 22, p. 8540, doi. 10.1002/cam4.3449
- By:
- Publication type:
- Article
Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIE extranodal natural killer/T‐cell lymphoma, nasal type.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 7, p. 3349, doi. 10.1002/cam4.2214
- By:
- Publication type:
- Article
Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.741142
- By:
- Publication type:
- Article